Esophagitis: A novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 3, 2013, Pages

  Srivastava, Neeharika ^a   Vanderlaan, Paul A ^a   Kelly, Ciaran P ^a   Costa, Daniel B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; OMEPRAZOLE; ONDANSETRON;

AGED; ARTICLE; BRONCHUS BIOPSY; CASE REPORT; CHINESE; DRUG WITHDRAWAL; DYSPHAGIA; ENDOBRONCHIAL ULTRASONOGRAPHY; ESOPHAGITIS; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; ODYNOPHAGIA; PRIORITY JOURNAL; SIDE EFFECT; THORAX PAIN; VISION; WILD TYPE;

EID: 84874089132     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31827e2451     Document Type: Article

References (5)

1. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 2012;7: 1086-1090.
2. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363: 1693-1703.
3. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13: 1011-1019.
4. Gaughan EM, Costa DB. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 2011;3: 113-125.
5. Pfizer Inc. Crizotinib (Xalkori) full prescribing information. February1, 2012. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=676. Accessed October 18, 2012.